User profiles for J.C. Grotta
James C GrottaDirector Mobile Stroke Unit and Stroke Research, Memorial Hermann Hospital Verified email at uth.tmc.edu Cited by 124873 |
Scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the …
Purpose— To critically review and evaluate the science behind individual eligibility criteria (indication/inclusion
and contraindications/exclusion criteria) for intravenous recombinant …
and contraindications/exclusion criteria) for intravenous recombinant …
[HTML][HTML] Absolute risk and predictors of the growth of acute spontaneous intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data
…, KS Butcher, SM Seyedsaadat, JC Grotta… - The Lancet …, 2018 - thelancet.com
Background Intracerebral haemorrhage growth is associated with poor clinical outcome and
is a therapeutic target for improving outcome. We aimed to determine the absolute risk and …
is a therapeutic target for improving outcome. We aimed to determine the absolute risk and …
Acute stroke imaging research roadmap II
Society of Neuroradiology, and the Foundation of the American Society of Neuroradiology
sponsored a series of working group meetings> 12 months, with the final meeting occurring …
sponsored a series of working group meetings> 12 months, with the final meeting occurring …
Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
Background Early administration of intravenous recombinant tissue plasminogen activator (rt-PA)
after ischaemic stroke improves outcome. Previous analysis of combined data from …
after ischaemic stroke improves outcome. Previous analysis of combined data from …
[HTML][HTML] Trial of endovascular thrombectomy for large ischemic strokes
Background Trials of the efficacy and safety of endovascular thrombectomy in patients with
large ischemic strokes have been carried out in limited populations. Methods We performed a …
large ischemic strokes have been carried out in limited populations. Methods We performed a …
[HTML][HTML] Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke
AV Alexandrov, CA Molina, JC Grotta… - … England Journal of …, 2004 - Mass Medical Soc
Background Transcranial Doppler ultrasonography that is aimed at residual obstructive
intracranial blood flow may help expose thrombi to tissue plasminogen activator (t-PA). Our …
intracranial blood flow may help expose thrombi to tissue plasminogen activator (t-PA). Our …
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study
Background: The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA
Stroke Study showed a similar percentage of intracranial hemorrhage and good outcome in …
Stroke Study showed a similar percentage of intracranial hemorrhage and good outcome in …
Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator
AV Alexandrov, JC Grotta - Neurology, 2002 - AAN Enterprises
Background: Arterial reocclusion has not been systematically studied despite the fact that 13%
of patients in the National Institute of Neurological Diseases and Stroke rt-PA Trial …
of patients in the National Institute of Neurological Diseases and Stroke rt-PA Trial …
[PDF][PDF] Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease
The vascular smooth muscle cell (SMC)-specific isoform of α-actin (ACTA2) is a major
component of the contractile apparatus in SMCs located throughout the arterial system. …
component of the contractile apparatus in SMCs located throughout the arterial system. …
[HTML][HTML] Prospective, multicenter, controlled trial of mobile stroke units
Background Mobile stroke units (MSUs) are ambulances with staff and a computed tomographic
scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than …
scanner that may enable faster treatment with tissue plasminogen activator (t-PA) than …